Clinical Trials Browser

Phase 2 × tenalisib × Other hematologic neoplasm × Clear all

NCT04204057 2024-08-13

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

21 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell